Covered recipient · General Payments record
CAITLYN PROGEBIN
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Women's Health
General Payments · PY2022–2024
$760.20
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $373.52 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $108.24 | 4 |
| Biogen, Inc. | $106.63 | 4 |
| Daiichi Sankyo Inc. | $106.58 | 5 |
| Exeltis, USA Inc. | $18.71 | 1 |
| Organon LLC | $17.82 | 1 |
| Sumitomo Pharma America, Inc. | $15.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $21.68 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139461978 | CMS |
| Astellas Pharma US Inc | $34.99 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139555659 | CMS |
| Astellas Pharma US Inc | $16.58 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139520914 | CMS |
| Astellas Pharma US Inc | $34.99 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139560301 | CMS |
| Biogen, Inc. | $29.33 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104826942 | CMS |
| Biogen, Inc. | $23.58 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104830394 | CMS |
| Biogen, Inc. | $25.98 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104868392 | CMS |
| Biogen, Inc. | $27.74 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104853584 | CMS |
| Daiichi Sankyo Inc. | $28.32 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089464552 | CMS |
| Daiichi Sankyo Inc. | $20.79 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089464554 | CMS |
| Daiichi Sankyo Inc. | $20.13 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089464550 | CMS |
| Daiichi Sankyo Inc. | $19.21 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089464556 | CMS |
| Daiichi Sankyo Inc. | $18.13 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089464558 | CMS |
| Exeltis, USA Inc. | $18.71 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150018259 | CMS |
| Organon Llc | $17.82 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136239993 | CMS |
| Sumitomo Pharma America, Inc. | $15.54 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148989180 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.